Crystalline forms of the CXCR7 receptor antagonist (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide

1. A crystalline form of a compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide

having an X-ray powder diffraction pattern wherein:

a. peaks are present in the X-ray powder diffraction pattern at the following angles of refraction 2θ: 3.6°, 8.2°, and 18.3°; corresponding to crystalline form 1; or

b. peaks are present in the X-ray powder diffraction pattern at the following angles of refraction 2θ: 6.7°, 8.5°, and 10.9°; corresponding to crystalline form 2; or

c. peaks are present in the X-ray powder diffraction pattern at the following angles of refraction 2θ: 8.2° 17.9°, and 21.0°; corresponding to crystalline form 3;

wherein said X-ray powder diffraction pattern is obtained from combined Cu Kα1 and Kα2 radiation, without Kα2 stripping; and the accuracy of the 2θ values is in the range of 2θ+/−0.2°.

2. The crystalline form of the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide according to claim 1 , wherein peaks are present in the X-ray powder diffraction pattern at the following angles of refraction 2θ: 3.6°, 7.2°, 8.2°, 8.7°, and 18.3°.

3. The crystalline form of the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide according to claim 1 , peaks are present in the X-ray powder diffraction pattern at the following angles of refraction 2θ: 3.6°, 7.2°, 8.2°, 8.7°, 9.1°, 10.8°, 13.9°, 17.0°, 17.5°, and 18.3°.

4. The crystalline form of the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide according to claim 2 , which essentially shows the X-ray powder diffraction pattern as depicted in FIG. 1 .

5. The crystalline form of the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide according to claim 2 , which has an endothermal event at about 259° C. as determined by differential scanning calorimetry.

6. The crystalline form of the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide according to claim 2 , wherein said crystalline form is an anhydrate.

7. The crystalline form of the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide according to claim 2 , corresponding to crystalline form 1, obtainable by:

a) mixing 10 mg of (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide with 1 mL of methanol, or mixing 20 mg of (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide with 1 mL of an about 3 to 1 mixture of methanol and acetonitrile;

b) dissolving (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide by heating to about 65° C. with a ramp of 0.1° C./min;

c) cooling the mixture to about 20° C. by using a ramp of 0.1° C./min; and

d) filtering and drying the product.

8. The crystalline form of the compound ((3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide according to claim 1 , wherein:

a. peaks are present in the X-ray powder diffraction pattern at the following angles of refraction 2θ: 6.7°, 8.5°, 10.9°, 13.2°, and 14.5°; or

b. peaks are present in the X-ray powder diffraction pattern at the following angles of refraction 2θ: 6.8°, 8.2°, 14.1°, 17.9°, and 21.0°.

9. The crystalline form of the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide according to claim 8 , wherein:

a. peaks are present in the X-ray powder diffraction pattern at the following angles of refraction 2θ: 6.7°, 8.5°, 10.9°, 13.2°, and 14.5°; which essentially shows the X-ray powder diffraction pattern as depicted in FIG. 2 ; or

b. peaks are present in the X-ray powder diffraction pattern at the following angles of refraction 2θ: 6.8°, 8.2°, 14.1°, 17.9°, and 21.0°; which essentially shows the X-ray powder diffraction pattern as depicted in FIG. 3 .

10. The crystalline form of the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide according to claim 8 , wherein said crystalline form is an anhydrate and peaks are present in the X-ray powder diffraction pattern at the following angles of refraction 2θ: 6.7°, 8.5°, 10.9°, 13.2°, and 14.5°.

11. The crystalline form of the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide according to claim 8 , wherein said crystalline form is an anhydrate and peaks are present in the X-ray powder diffraction pattern at the following angles of refraction 2θ: 6.8°, 8.2°, 14.1°, 17.9°, and 21.0°.

12. A pharmaceutical composition comprising as active ingredient a crystalline form of the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide according to claim 1 , and at least one pharmaceutically acceptable carrier.

13. A pharmaceutical composition comprising the crystalline form of the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide according to claim 3 , and at least one pharmaceutically acceptable carrier material.

14. A method for the treatment of cancer comprising administering to a patient in need thereof a crystalline form of the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide according to claim 1 .

15. A method for the treatment of cancer comprising administering to a patient in need thereof a crystalline form of the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide according to claim 3 .

16. A method for treatment of cancer comprising administering to a patient an effective amount of a crystalline form of the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3- carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide according to claim 10 .

17. A pharmaceutical composition comprising as active ingredient a crystalline form of the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide according to claim 10 , and at least one pharmaceutically acceptable carrier.

18. A pharmaceutical composition comprising as active ingredient a crystalline form of the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide according to claim 11 , and at least one pharmaceutically acceptable carrier.

19. A method for treatment of cancer comprising administering to a patient an effective amount of a crystalline form of the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3- carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide according to claim 11 .

20. A method for treatment of cancer according to claim 14 , wherein the cancer is selected from carcinomas, leukemia, sarcomas, lymphomas, myelomas, metastatic cancers, brain tumors, neuroblastomas, pancreatic cancer, lung and breast cancer, endometrial cancer, head and neck cancer, or ovarian cancer.

21. A method for treatment of autoimmune disorders which have an inflammatory component selected from inflammatory demyelinating diseases, multiple sclerosis (MS), Guillain Barré syndrome, rheumatoid arthritis (RA), inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), lupus nephritis, and auto-immune encephalomyelitis; comprising administering to a patient an effective amount of a crystalline form of the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}- piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide according to claim 1 .

22. A method for treatment of autoimmune disorders which have an inflammatory component selected from inflammatory demyelinating diseases, multiple sclerosis (MS), Guillain Barré syndrome, rheumatoid arthritis (RA), inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), lupus nephritis, and auto-immune encephalomyelitis; comprising administering to a patient an effective amount of a crystalline form of the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}- piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide according to claim 3 .

23. A method for treatment of autoimmune disorders which have an inflammatory component selected from inflammatory demyelinating diseases, multiple sclerosis (MS), Guillain Barré syndrome, rheumatoid arthritis (RA), inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), lupus nephritis, and auto-immune encephalomyelitis; comprising administering to a patient an effective amount of a crystalline form of the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}- piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide according to claim 10 .

24. A method for treatment of autoimmune disorders which have an inflammatory component selected from inflammatory demyelinating diseases, multiple sclerosis (MS), Guillain Barré syndrome, rheumatoid arthritis (RA), inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), lupus nephritis, and auto-immune encephalomyelitis; comprising administering to a patient an effective amount of a crystalline form of the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}- piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide according to claim 11 .

25. A method for treatment of inflammatory diseases selected from

lung inflammatory diseases selected from asthma, chronic obstructive pulmonary disorder (COPD), and acute lung injury; and

atherosclerosis;

comprising administering to a patient an effective amount of a crystalline form of the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide according to claim 1 .

26. A method for treatment of inflammatory diseases selected from

lung inflammatory diseases selected from asthma, chronic obstructive pulmonary disorder (COPD), and acute lung injury; and

atherosclerosis;

comprising administering to a patient an effective amount of a crystalline form of the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide according to claim 3 .

27. A method for treatment of inflammatory diseases selected from

lung inflammatory diseases selected from asthma, chronic obstructive pulmonary disorder (COPD), and acute lung injury; and

atherosclerosis;

comprising administering to a patient an effective amount of a crystalline form of the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide according to claim 10 .

28. A method for treatment of inflammatory diseases selected from

lung inflammatory diseases selected from asthma, chronic obstructive pulmonary disorder (COPD), and acute lung injury; and

atherosclerosis;

comprising administering to a patient an effective amount of a crystalline form of the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide according to claim 11 .

29. A method for treatment of fibrosis; comprising administering to a patient an effective amount of a crystalline form of the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide according to claim 1 .

30. A method for treatment of fibrosis; comprising administering to a patient an effective amount of a crystalline form of the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide according to claim 3 .

31. A method for treatment of fibrosis; comprising administering to a patient an effective amount of a crystalline form of the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide according to claim 10 .

32. A method for treatment of fibrosis; comprising administering to a patient an effective amount of a crystalline form of the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide according to claim 11 .